Search Results - "Peeters, M. Vrancken"

Management of the axilla after neoadjuvant chemotherapy for breast cancer by Vrancken Peeters, M. T. F. D.

“…Minor international differences…”
Get full text

Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure by van der Noordaa, M. E. M., van Duijnhoven, F. H., Straver, M. E., Groen, E. J., Stokkel, M., Loo, C. E., Elkhuizen, P. H. M., Russell, N. S., Vrancken Peeters, M. T. F. D.

“…Background Axillary lymph node dissection (ALND) is frequently performed for node-positive (cN+) breast cancer patients. Combining positron emission…”
Get full text

Added value of repeat sentinel lymph node biopsy in FDG-PET/CT node-negative patients with ipsilateral breast cancer recurrence by Haarsma, R., van Loevezijn, A. A., Donswijk, M. L., Scholten, A. N., Vrancken Peeters, M. T. F. D., van Duijnhoven, F. H.

“…Purpose Repeat sentinel lymph node biopsy (rSLNB) has been suggested for axillary staging in clinically node-negative (cN0) patients with ipsilateral breast…”
Get full text

Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges by Heil, J., Kuerer, H.M., Pfob, A., Rauch, G., Sinn, H.P., Golatta, M., Liefers, G.J., Vrancken Peeters, M.J.

“…In patients with operable early breast cancer, neoadjuvant systemic treatment (NST) is a standard approach. Indications have expanded from downstaging of…”
Get full text

Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer by Straver, M. E., Loo, C. E., Alderliesten, T., Rutgers, E. J. T., Vrancken Peeters, M. T. F. D.

“…Background: An important benefit of neoadjuvant chemotherapy is the increased potential for breast‐conserving surgery. At present the response of axillary…”
Get full text

Radioactive seed localization in breast cancer treatment by Janssen, N. N. Y., Nijkamp, J., Alderliesten, T., Loo, C. E., Rutgers, E. J. T., Sonke, J.-J., Vrancken Peeters, M. T. F. D.

“…Background Breast cancer screening, improved imaging and neoadjuvant systemic therapy (NST) have led to increased numbers of non‐palpable tumours suitable for…”
Get full text

Breast-contour preserving procedures for early-stage breast cancer: a population-based study of the trends, variation in practice and predictive characteristics in Denmark and the Netherlands by Heeg, E., Jensen, M. B., Mureau, M. A. M., Ejlertsen, B., Tollenaar, R. A. E. M., Christiansen, P. M., Vrancken Peeters, M. T. F. D.

“…Purpose Breast-contour preservation (BCP) is possible for most women treated for early-stage breast cancer. BCP can be defined as primary breast-conserving…”
Get full text

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy by Straver, M. E., Rutgers, E. J. Th, Rodenhuis, S., Linn, S. C., Loo, C. E., Wesseling, J., Russell, N. S., Oldenburg, H. S. A., Antonini, N., Vrancken Peeters, M. T. F. D.

“…Background Breast cancer is increasingly considered a heterogeneous disease. The aim of this study was to assess the differences between histological and…”
Get full text

Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics by Lips, E. H., Mulder, L., de Ronde, J. J., Mandjes, I. A. M., Vincent, A., Vrancken Peeters, M. T. F. D., Nederlof, P. M., Wesseling, J., Rodenhuis, S.

“…A pathological complete remission (pCR) is rarely achieved by neoadjuvant chemotherapy in estrogen receptor-positive (ER+) HER2-negative (HER2−) tumors…”
Get full text

Nationwide population‐based study of the impact of immediate breast reconstruction after mastectomy on the timing of adjuvant chemotherapy by Heeg, E., Harmeling, J. X., Becherer, B. E., Marang‐van de Mheen, P. J., Vrancken Peeters, M. T. F. D., Mureau, M. A. M.

“…Background Initiation of adjuvant chemotherapy within 6–12 weeks after mastectomy is recommended by guidelines. The aim of this population‐based study was to…”
Get full text

Combined PET–CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node‐positive breast cancer after neoadjuvant therapy by Koolen, B. B., Donker, M., Straver, M. E., van der Noordaa, M. E. M., Rutgers, E. J. T., Valdés Olmos, R. A., Vrancken Peeters, M. J. T. F. D.

“…Background The treatment of axillary lymph node metastases after neoadjuvant systemic therapy (NST) remains debatable and axillary lymph node dissection (ALND)…”
Get full text

Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy by Koolen, B. B., Vrancken Peeters, M. J. T. F. D., Wesseling, J., Lips, E. H., Vogel, W. V., Aukema, T. S., van Werkhoven, E., Gilhuijs, K. G. A., Rodenhuis, S., Rutgers, E. J. Th, Valdés Olmos, R. A.

“…Purpose The aim of this study was to evaluate the association of primary tumour 18 F-fluorodeoxyglucose (FDG) uptake with clinical, histopathological and…”
Get full text

Internal Responsiveness of EQ-5D-5L and EORTC QLQ-C30 in Dutch Breast Cancer Patients during the First Year Post-Surgery: A Longitudinal Cohort Study by Vrancken Peeters, Noëlle J M C, van Til, Janine A, Huberts, Anouk S, Siesling, Sabine, Husson, Olga, Koppert, Linetta B

“…The EuroQoL 5-Dimension 5-Level questionnaire (EQ-5D-5L) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire…”
Get full text

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy by Lips, E.H., Mulder, L., Hannemann, J., Laddach, N., Vrancken Peeters, M.T.F.D., van de Vijver, M.J., Wesseling, J., Nederlof, P.M., Rodenhuis, S.

“…Tumors with homologous recombination deficiency (HRD), such as BRCA1-associated breast cancers, are not able to reliably repair DNA double-strand breaks (DSBs)…”
Get full text

Surgical complications of skin sparing mastectomy and immediate prosthetic reconstruction after neoadjuvant chemotherapy for invasive breast cancer by Donker, M, Hage, J.J, Woerdeman, L.A.E, Rutgers, E.J.Th, Sonke, G.S, Vrancken Peeters, M.-J.T.F.D

“…Abstract Background Neoadjuvant chemotherapy is gaining acceptance as an option for breast cancer treatment, particularly in young women. These women may seek…”
Get full text

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure by Jebbink, M., van Werkhoven, E., Mandjes, I. A. M., Wesseling, J., Lips, E. H., Vrancken Peeters, M.-J. T. D. F., Loo, C. E., Sonke, G. S., Linn, S. C., Falo Zamora, C., Rodenhuis, S.

“…The Neoadjuvant response index (NRI) has been proposed as a simple measure of downstaging by neoadjuvant treatment in breast cancer. It was previously found to…”
Get full text

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer by Rigter, L S, Loo, C E, Linn, S C, Sonke, G S, van Werkhoven, E, Lips, E H, Warnars, H A, Doll, P K, Bruining, A, Mandjes, I A, Vrancken Peeters, M J, Wesseling, J, Gilhuijs, K G, Rodenhuis, S

“…Background: Changing the neoadjuvant chemotherapy regimen in insufficiently responding breast cancer is not a standard policy. We analysed a series of patients…”
Get full text

Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness by Kregting, Lindy M, Vrancken Peeters, Noëlle J M C, Clarijs, Marloes E, Koppert, Linetta B, Korfage, Ida J, van Ravesteyn, Nicolien T

“…In breast cancer research, utility assumptions are outdated and inconsistent which may affect the results of quality adjusted life year (QALY) calculations and…”
Get full text

Outcomes Associated With Intracranial Aneurysm Treatments Reported as Safe, Effective, or Durable: A Systematic Review and Meta-Analysis by Volovici, Victor, Verploegh, Iris S., Satoer, Djaina, Vrancken Peeters, Noëlle J. M. C., Sadigh, Yasmin, Vergouwen, Mervyn D. I., Schouten, Joost W., Bruggeman, Gavin, Pisica, Dana, Yildirim, Gizem, Cozar, Ayca, Muller, Femke, Zidaru, Ana-Maria, Gori, Kelsey, Tzourmpaki, Nefeli, Schnell, Esther, Thioub, Mbaye, Kicielinski, Kimberly, van Doormaal, Pieter-Jan, Velinov, Nikolay, Boutarbouch, Mahjouba, Lawton, Michael T., Lanzino, Giuseppe, Amin-Hanjani, Sepideh, Dammers, Ruben, Meling, Torstein R.

“…Importance Testing new medical devices or procedures in terms of safety, effectiveness, and durability should follow the strictest methodological rigor before…”
Get full text

Contemporary Series of Morbidity and Mortality after Lower Limb Amputation by Ploeg, A.J., Lardenoye, J.-W., Vrancken Peeters, M.-P.F.M., Breslau, P.J.

“…This study was performed in order to assess morbidity and mortality associated with major lower extremity amputation according to an extensive complication…”
Get full text